Definition
Competitive inhibition is a form of reversible enzyme inhibition in which an inhibitor molecule competes with the substrate for binding to the active site of an enzyme. The inhibitor typically resembles the substrate’s structure, allowing it to occupy the active site without undergoing the catalytic reaction.
Mechanism
- Binding Site Competition – The inhibitor (I) and the substrate (S) both bind to the same site on the enzyme (E). When I is bound, the enzyme–substrate complex (ES) cannot form, and catalysis is prevented.
- Reversibility – The interaction is non‑covalent; both I and S can dissociate from the enzyme, allowing the reaction to resume when the inhibitor concentration decreases.
- Concentration Dependence – The degree of inhibition depends on the relative concentrations of substrate and inhibitor and on their respective affinities for the enzyme (quantified by their dissociation constants, K_i for the inhibitor and K_m for the substrate).
Kinetic Characteristics
In Michaelis–Menten kinetics, competitive inhibition modifies the apparent Michaelis constant (K_m) while leaving the maximal velocity (V_max) unchanged. The relationship can be expressed as:
$$ v = \frac{V_{\max}[S]}{K_m\left(1 + \frac{[I]}{K_i}\right) + [S]} $$
where:
- v is the reaction velocity,
- [S] and [I] are the concentrations of substrate and inhibitor, respectively,
- K_i is the inhibition constant.
Graphically, a Lineweaver–Burk plot of 1/v versus 1/[S] shows intersecting lines at the y‑axis, indicating identical V_max values but increased slopes proportional to (1 + [I]/K_i).
Biological Significance
Competitive inhibition is a common regulatory mechanism in metabolic pathways, allowing endogenous molecules to modulate enzyme activity. It also underlies the pharmacological action of many drugs that act as enzyme inhibitors, such as:
- Methotrexate, a competitive inhibitor of dihydrofolate reductase used in chemotherapy.
- Statins, which competitively inhibit HMG‑CoA reductase, reducing cholesterol synthesis.
- Angiotensin‑converting enzyme (ACE) inhibitors, which compete with the natural substrate angiotensin I.
Practical Applications
- Drug Design – Knowledge of competitive inhibition guides the development of substrate analogues that selectively block target enzymes.
- Biotechnological Assays – Competitive inhibitors are employed to assess enzyme kinetics and to distinguish between different inhibition types.
- Clinical Diagnostics – Measurement of inhibition constants can aid in evaluating drug efficacy and potential drug–drug interactions.
Related Concepts
- Non‑competitive inhibition: inhibitor binds to a site distinct from the active site, decreasing V_max without affecting K_m.
- Uncompetitive inhibition: inhibitor binds only to the enzyme–substrate complex, lowering both V_max and K_m.
- Mixed inhibition: combines features of competitive and non‑competitive inhibition.
References
- Segel, I. H. (1993). Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. Wiley.
- Copeland, R. A. (2013). Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. Wiley.
- Nelson, D. L., & Cox, M. M. (2017). Lehninger Principles of Biochemistry (7th ed.). W. H. Freeman.
